ClinicalTrials.gov
public full text
Public Domain
Angiotensin Converting Enzyme Inhibitors and Periprocedural Myocardial Infarction
Metabolic syndrome (MS) has been reported as a risk for cardiovascular events. The aim of the present cohort study is to investigate whether ACEi therapy reduces the rate of periprocedural myocardial injury (PPMI) after elective percutaneous coronary intervention (PCI) among patients with metabolic syndrome.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Acute Myocardial Infarction and Unstable Angina Patients With PCSK9 Inhibitor Usage Study#908356
- Appropriateness of Angioplasty in Patients With Chronic Coronary Syndromes#842718
- Prognostic Role of Lipoprotein(a) in Elective Percutaneous Coronary Revascularization#992337
- Angiomax® or Unfractionated Heparin for Patients Undergoing Percutaneous Coronary Intervention#858026
- Outcomes of Angiotensin Converting Enzyme Inhibitor Management Strategies Prior to Coronary Artery Bypass#806887
Record · ID 1057068
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive